Reactivity and site of vasomotion in pulmonary vessels of chronically hypoxic rats: relation to structural changes.
The high pressure muscular pulmonary circulation of chronically hypoxic (CH) rats was compared with the low pressure circuit in control (C) rats; differences were found in the effects of lung inflation, in pressure/flow relations during lung inflation, in reactivity to autocoids, and in responses to pulmonary dilator drugs. Isolated blood-perfused lungs of CH rats (2 to 3 wk in 10% O2) were compared with those of C rats kept in air. High inflation (alveolar) pressure (Palv) caused a rise in pulmonary artery pressure (Ppa) close to delta Palv in both groups; in CH rats, Ppa continued to rise, whereas it adapted to a lower level in C rats. Pressure-flow (P/Q) lines were measured at high and low Palv, all in Zone 2 state. In normoxia, high Palv caused a parallel shift in the P/Q line close to delta Palv in both C and CH rats. However, during hypoxic pulmonary vasoconstriction (HPV), high Palv caused a shift in the P/Q line less than delta Palv in C rats and greater than delta Palv in CH rats. Similar differences between C and CH rats were seen during constriction caused by almitrine, a drug that simulates HPV. Thus, these stimuli affect vessels that are functionally "extra-alveolar" in C rats but functionally "alveolar" in CH rats. We consider whether vasoconstriction by hypoxia and almitrine moves peripherally to the newly muscularized alveolar arterioles that are found in CH rats. Reactivity of lung vessels to bradykinin, angiotensin-1, and platelet-activating factor was greater in CH than in C rats, possibly also associated with muscularization of arterioles in the former.(ABSTRACT TRUNCATED AT 250 WORDS)
Barer
G R
GR
University Department of Medicine, Royal Hallamshire Hospital, Sheffield, United Kingdom.
Cai
Y N
YN
Russell
P C
PC
Emery
C J
CJ
D000241:Adenosine / Q000494:pharmacology; D019830:Adenosine-5'-(N-ethylcarboxamide); D015765:Almitrine / Q000494:pharmacology; D000803:Angiotensin I / Q000494:pharmacology; D000818:Animals; D001920:Bradykinin / Q000494:pharmacology; D002908:Chronic Disease; D000860:Hypoxia / Q000473:pathology / Q000503:physiopathology*; D008297:Male; D010972:Platelet Activating Factor / Q000494:pharmacology; D011652:Pulmonary Circulation; D011719:Pyrazines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values; D012119:Respiration; D014661:Vasoconstriction; D014665:Vasodilator Agents / Q000494:pharmacology; D014666:Vasomotor System / Q000187:drug effects / Q000503:physiopathology*
D010972:Platelet Activating Factor; D011719:Pyrazines; D014665:Vasodilator Agents; D019830:Adenosine-5'-(N-ethylcarboxamide); D000803:Angiotensin I; D015765:Almitrine; D000241:Adenosine; D001920:Bradykinin; C017953:tetramethylpyrazine